628 related articles for article (PubMed ID: 33102749)
61. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Yamamura S; Nakano D; Hashida R; Tsutsumi T; Kawaguchi T; Okada M; Isoda H; Takahashi H; Matsuse H; Eguchi Y; Sumida Y; Nakajima A; Gerber L; Younossi ZM; Torimura T
J Gastroenterol Hepatol; 2021 Mar; 36(3):629-636. PubMed ID: 32627871
[TBL] [Abstract][Full Text] [Related]
62. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
63. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
[TBL] [Abstract][Full Text] [Related]
64. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
Tokushige K; Hashimoto E; Kodama K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
[TBL] [Abstract][Full Text] [Related]
65. Epidemiology and natural history of non-alcoholic fatty liver disease.
Fazel Y; Koenig AB; Sayiner M; Goodman ZD; Younossi ZM
Metabolism; 2016 Aug; 65(8):1017-25. PubMed ID: 26997539
[TBL] [Abstract][Full Text] [Related]
66. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
Le TA; Loomba R
J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
[TBL] [Abstract][Full Text] [Related]
67. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
[TBL] [Abstract][Full Text] [Related]
68. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
69. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?
Hashimoto E; Tokushige K
Hepatol Res; 2012 Jan; 42(1):1-14. PubMed ID: 21917086
[TBL] [Abstract][Full Text] [Related]
70. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid.
Eshraghian A; Nikeghbalian S; Geramizadeh B; Kazemi K; Shamsaeefar A; Malek-Hosseini SA
Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):572-578. PubMed ID: 31611031
[TBL] [Abstract][Full Text] [Related]
71. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
[TBL] [Abstract][Full Text] [Related]
72. Clinicopathological features of non-alcoholic fatty liver disease.
Sugimoto K; Takei Y
Hepatol Res; 2011 Oct; 41(10):911-20. PubMed ID: 21951869
[TBL] [Abstract][Full Text] [Related]
73. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
74. Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".
Manti S; Romano C; Chirico V; Filippelli M; Cuppari C; Loddo I; Salpietro C; Arrigo T
Hepat Mon; 2014 May; 14(5):e17641. PubMed ID: 24829591
[TBL] [Abstract][Full Text] [Related]
75. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
[TBL] [Abstract][Full Text] [Related]
76. Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis.
Villeret F; Dharancy S; Erard D; Abergel A; Barbier L; Besch C; Boillot O; Boudjema K; Coilly A; Conti F; Corpechot C; Duvoux C; Faitot F; Faure S; Francoz C; Giostra E; Gugenheim J; Hardwigsen J; Hilleret MN; Hiriart JB; Houssel-Debry P; Kamar N; Lassailly G; Latournerie M; Pageaux GP; Samuel D; Vanlemmens C; Saliba F; Dumortier J
JHEP Rep; 2023 Mar; 5(3):100668. PubMed ID: 36852108
[TBL] [Abstract][Full Text] [Related]
77. Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis.
Wang X; Li W; Zhang Y; Yang Y; Qin G
Int J Clin Exp Med; 2015; 8(10):17221-34. PubMed ID: 26770315
[TBL] [Abstract][Full Text] [Related]
78. Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma.
Takakura K; Oikawa T; Nakano M; Saeki C; Torisu Y; Kajihara M; Saruta M
Front Oncol; 2019; 9():762. PubMed ID: 31456946
[TBL] [Abstract][Full Text] [Related]
79. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Bertot LC; Adams LA
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
[TBL] [Abstract][Full Text] [Related]
80. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
